Viridian Therapeutics
VRDN
9 hedge funds and large institutions have $303K invested in Viridian Therapeutics in 2016 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 9 → 9 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
25% less capital invested
Capital invested by funds: $406K → $303K (-$103K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$14.7K |
| 2 |
Renaissance Technologies
New York
|
+$8.34K |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$736 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$18.3K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$12.1K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
-$12K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$9K |
| 5 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
-$8.34K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
HighTower Advisors
Chicago,
Illinois
| $174K | – | – | – |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $44K | -$18.3K | -149 | -25% |
|
|
PCM
3
Perkins Capital Management
Wayzata,
Minnesota
| $30K | -$8.34K | -68 | -18% |
|
|
ICAS
4
Investors Capital Advisory Services
Lynnfield,
Massachusetts
| $16K | – | – | – |
|
|
5
Citadel Advisors
Miami,
Florida
| $15K | -$12.1K | -99 | -39% |
|
|
6
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $11K | +$14.7K | +120 | New |
|
7
Creative Planning
Overland Park,
Kansas
| $6K | – | – | – |
|
|
8
Renaissance Technologies
New York
| $6K | +$8.34K | +68 | New |
|
|
BFA
9
BlackRock Fund Advisors
San Francisco,
California
| $1K | +$736 | +6 | New |
|
|
VKH
10
Virtu KCG Holdings
New York
| – | -$12K | -101 | Closed |
|
|
11
UBS Group
Zurich,
Switzerland
| – | -$9K | -79 | Closed |
|
12
Goldman Sachs
New York
| – | -$6K | -54 | Closed |
|
VRDN Hedge Fund Activity: Q2 2016 in Review
9 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q2 2016, worth a combined $303K — down 25% from $406K a quarter earlier.
Fund positioning in VRDN was balanced in Q2 2016: 3 funds opened new positions, 3 closed out, 0 added to existing stakes and 3 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $14.7K. The largest seller was Vanguard Group, cutting an estimated $18.3K.
- 9 institutional investors held Viridian Therapeutics (VRDN) as of Q2 2016, unchanged from Q1 2016.
- Funds reported $303K of Viridian Therapeutics stock for Q2 2016, down 25% quarter-over-quarter.
- 3 funds opened new Viridian Therapeutics positions in Q2 2016 and 3 closed out, a net change of 0 holders.
- The largest Viridian Therapeutics buyer in Q2 2016 was Susquehanna International Group, an estimated $14.7K added.
- The largest Viridian Therapeutics seller in Q2 2016 was Vanguard Group, an estimated $18.3K sold.
Based on aggregated 13F filings for Q2 2016.